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 More than 365,000 of unborn children are at risk of getting HIV infection in the developing 
world through "vertical" transmission. Although, ARVs are being used to reduce maternal HIV 
transmission, limited information exists indicating their impact on the trend of HIV prevalence 
among infants born to HIV infected mothers. 
OBJECTIVE 
 To determine the trend of HIV infection among infants born to HIV infected mothers in 
relation to specific ARVs administered to pregnant women and lactating mothers of 18 months 
and below infants. 
METHODOLOGY
 Dried blood spot samples in the following quantities per year thus, in 2010, n = 4,210, in 
2011, n=4,093, in 2012, n=4,686, in 2013, n=3,080 were collected from infants aged ≤18 months 
whose mothers were HIV positive. The samples were analyzed using Cobas Polymerase Chain 
Reaction Assay in early infant diagnosis laboratory at the Center for Infectious and Parasitic 
Diseases Control Research, Kenya Medical Research Institute (KEMRI).
RESULTS
 Out of the total number of samples tested 2010, 409(9.7%) tested HIV positive. In 2011, 
350(8.5%), in 2012, 368(7.9%) and in 2013, 221(7.2%) were HIV positive respectively. The trend 
of HIV in infants whose mothers had been put on various ARVs was as follows: AZT+3TC +EFV, 
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in 2010, the number was 10.4%. In 2011, it moved to 9.1%, in 2012, to 6.3% and 2013, dropped to 
6.0%. AZT+3TC+NVP, in 2010, the number was 7.1%, in  2011, moved to 6.1%, in 2012, falling 
to 4.7% and 2013 to3.9%. SdNVP, in 2010, the number was 10.3%. In 2011, moved to 7.4%, in 
2012, dropping to 6.2% and in 2013, at 6.0%. Those mothers who had not been given any ARVs, 
their infants had HIV prevalence as follows: in 2010, the number was 11.2%. In 2011, it climbed 
to 12.6%, moving to 12.7% in 2012, and 12.9% in 2013.
CONCLUSION
 There was direct relationship between specific ARV administration and HIV infection 
among those infants. That was evident by the fact that, HIV appeared to decrease with sub-
sequent years of provision of specific drugs. However, HAART (AZT+3TC+ EFV) seemed to 
provide greater impact in HIV prevention compared to other HAART (AZT+3TC+NVP) and 
SdNVP. The worst groups are those not on any ARVs. Single-dose Nevirapine commonly is used 
for prevention event-hough prior studies have shown exposure to it develop drug resistance, which 
can compromise the effective not only of itself, but also other non-nucleoside reverse transcriptase 
inhibitors (NNRTIs)
RECOMMENDATION
 There is need for all HIV positive pregnant women to be put on ARVs and monitored for 
ARVs uptake to reduce the transmission of HIV from mother to child.
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Summary
less than 5% annually. It could also avert more than 
one million new HIV infections among children by 
2015, while improving overall maternal and family 
health [3, 4].
 Management of a pregnant woman with HIV 
infection has evolved significantly over the past 25 
years in light of advancements in drug development. 
Greater understanding to the prevention of perinatal 
HIV transmission not overlooked. The risk of HIV 
transmission from mother to infant had declined to 
historically low levels with the use of Antiretroviral 
Medications [5, 6]
 Pregnant women with HIV infection should 
receive standard clinical, immunologic, and virologic 
evaluation. They should be offered appropriate 
Antiretroviral therapy for their own health and for 
prevention of perinatal transmission of HIV, consistent 
Introduction
 UNAIDS and the World Health Organization 
(WHO) estimated that in 2009 there were 230,000 to 
510,000 new HIV infections worldwide among children 
aged 0–15 years of age [1]. 
 Over 95% of these infections occurred in 
resource-limited settings, primarily Sub-Saharan 
Africa. Up to 90% of the infections resulted from 
mother-to-child transmission (MTCT) [2]. 
 The World Health Organization estimates  the 
risk of transmission ranges from 15 to 30% in non-
breastfeeding populations and from 20 to 45% in 
breastfeeding populations [3].
 Currently more than half of these infants 
who do not receive treatment die before their second 
birthday. Scaling up an effective Elimination of MTCT 
approach globally can reduce rates of transmission to 
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with the principles of treatment for non-pregnant adults 
[4, 7-9].
 Untreated mothers with a viral load >100,000 
copies/ml had a transmission risk of over 50%. The 
risk when viral loads are < 1000 copies/ml are less than 
1%[2, 4, 7].
 With the advent of Highly Active Antiretroviral 
Therapy (HAART), HIV-1 infection is now manageable 
as a chronic disease in patients who have access 
to medication and who achieve durable virologic 
suppression [10].
 HAART provides effective treatment options 
for Treatment - Naive and Treatment - Experienced 
patients. Also, the use of those Highly Active 
Antiretroviral Therapy (HAART) regimens has 
contributed to the decline in morbidity among patients 
with advanced HIV infection [10, 11] 
 The use of a combination Antiretroviral 
therapy (cART) regimen reduces plasma HIV RNA to 
undetectable levels that do help in lowering of the risk 
of transmission in an analysis of perinatal transmission 
in [5,151 
 HIV - infected women between 2000 and 2006 
in the United Kingdom and Ireland's overall perinatal 
transmission rate was 1.2%. A transmission rate of 0.8% 
was seen in women on ARV drugs for at least the last 
14 days of pregnancy, regardless of the type of ARV 
regimen or mode of delivery [6].
 Similar data from Canada of 1,707 HIV-
infected pregnant women followed between 1997 and 
2010 showed perinatal transmission was 1% in mothers 
receiving cART, and 0.4% if more than 4 weeks of 
cART was received [12].
 Two of the cART (AZT/3TC/NVP or EFV) 
have been evaluated in the context of prevention of 
mother-to-child transmission of HIV in under resourced 
settings result in excellent early virological suppression 
in mothers and those regimens were relatively safe and 
well tolerated. 
 That regimen was available and listed in the 
national guidelines of most low and middle - income 
countries and recommended for use in pregnant women 
in need  of ART. The most frequently used regimen 
include 3TC, AZT and NVP or EFV and the most widely 
used Antiretroviral in combined treatments is 3TC [13].
 
 Furthermore, starting AZT, 3TC, and Nevirapine 
(NVP) at 34 weeks in a mixed-feeding population has 
been found to reduce infant HIV-transmission or death 
at 7 months compared to a short-course regimen (RR 
0.39, 95% CI: 0.12-0.85) (Bae, 2008) [14].
 Since the efficacy of AZT was first demonstrated 
in 1994, a gradual decrease of vertical HIV transmission 
has been observed in Europe and the United States, 
reducing rates from 25% to below 2% [5, 15, 16].
 It is recommended that, AZT+3TC+EFV is 
one of the preferred regimens for ART-naïve patients 
initiating ART especially in pregnant women. However, 
It is not administered during the first trimester of 
pregnancy [17].
 Single-dose Nevirapine is commonly used 
for prevention of mother-to-child transmission in 
resource-limited settings, especially for women who 
do not receive care until the time of delivery. But prior 
studies have shown that women and infants exposed to 
a single dose often develop drug resistance, which can 
compromise the effective not only of Nevirapine itself, 
but also other non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) [18].
 A single dose of Nevirapine given to both 
mother and child reduced the rate of HIV transmission 
by almost 50% in a clinical trial in Uganda[19]. Because 
of its ease of administering and effectiveness, a single-
dose Nevirapine (SD-NVP) was widely used in poorly-
resourced countries like sub-Saharan Africa. The drug 
is administered at the onset of labor, and to the infant 
directly after birth [17]. 
 When used alone, SD-NVP reduces the rate 
of mother-to-child transmission by 50%. When used 
in concert with other drugs, SD-NVP was even more 
effective- reducing MTCT to as low as >1% (but, adding 
a high-cost, high-use drug does eliminate the practicality 
of SD-NVP). That was a simple and inexpensive method 
of decreasing the number of children infected with HIV 
in less-developed countries [20, 21]
 A subsequent study in Thailand showed that 
Prophylaxis with single-dose Nevirapine in addition to 
Zidovudine was more effective than Zidovudine alone 
[22].
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  These and other trials have led the World Health 
Organization to endorse the use of single-dose   
Nevirapine prophylaxis in many developing world 
settings as a cost-effective way of reducing mother-to-
child transmission. However, in the United States the 
Ugandan study was deemed flawed [23,24].
 Namibia’s first PMTCT guidelines of 2004 
were based on the use of single dose Nevirapine given 
to the mother at the onset of labour and a single dose 
given to the infant between 12 to 72 hours after delivery.
 In 2006, WHO released guidelines that 
recommended the use of combination regimens to 
improve efficacy of prevention. To this end, it has 
become necessary to revise Namibia’s first edition 
of the PMTCT guidelines to include the use of more 
efficacious regimens for PMTCT [25, 26]
 Several trials of short-course/single-dose 
peripartum ARV regimens have reported 18-mo 
transmission rates between 6.8% and 15.9% [27-29]. 
 In Kenya, the study has found that PMTCT 
programmes using single-dose Nevirapine administered 
to both mother and child are effective in reducing the 
early transmission of HIV in operational settings [30].
 Although HIV prevalence among the general 
population has fallen in Kenya, women continue to be 
disproportionately affected by the epidemic. 
 In 2012, 6.9 % of women were living with HIV 
compared with 4.2 percent of men [31]. 
 Kenya was committed to eliminating the 
mother-to-child transmission (MTCT) of HIV by 2015. 
Among the key strategies to Prevent The Mother-To-
Child Transmission (PMTCT) of HIV include universal 
uptake of HIV testing among pregnant women, as well 
as the provision of Antiretroviral Drugs (ARVs) [32]. 
 Indeed, in recent years, PMTCT efforts in 
Kenya have expanded rapidly. From 2008 to 2013, 
58,000 women annually were offered PMTCT services, 
out of an estimated 79,000 (76 percent coverage). 
 Between 2010 and 2013, PMTCT actual coverage 
fell from 86 percent to 70 percent. Nevertheless, this 
was due mainly to an increase in demand for PMTCT 
services [32]. 
 In 2009, the Kenyan government emphasized 
the importance of male involvement in PMTCT, and in 
2010 started a campaign to encourage partner testing, 
exclusive breastfeeding and the delivery of ART to 
children [33, 34]. 
 From 2010 to 2013, the percentage of women 
and their infants given ARVs during breastfeeding 
to prevent HIV transmission via this route increased 
from 65 percent to 70.6 percent. By comparison, male 
involvement in PMTCT remains very low in Kenya only 
4.5 percent [32]. 
 In such a country with increasing women and 
their infants given ARVs to prevent HIV Transmission, 
it is necessary to subsequently note the success of ARVs 
in the PMTCT program. 
 Therefore, the objectives of this study was to 
determine the trend of HIV infection among infants 
born to HIV infected mothers in relation to specific 
ARVs administration among pregnant women and 
mothers of 18 and below months infants from 2010 to 
2013.
Materials and Methodology
Study Site And Population
 Samples from referral health facilities 
(Busia, Bungoma, Kakamega and Vihiga county 
referral hospitals) in Western part of Keya providing 
Prevention of Mother - to - Child Transmission 
(PMTCT) and HIV management services such as 
HIV testing, CD4 counts, ARVs and anti-TB drugs 
for both the mothers and their infants were considered 
for this study. 
 All these health facilities are located in Western 
part of Kenya. The study population involved infants 
aged ≤ 18 months born to HIV-infected mothers. All 
the samples collected were analyzed in early infant 
diagnostics laboratory at the Center for Infectious and 
Parasitic Diseases Control Research, Kenya Medical 
Research Institute located in Alupe, Busia, Kenya.
Sample Collection
 The study utilized samples of the Protocol 
SSC No. 1066 on Early Infant Diagnosis of HIV. 
These samples were collected for EID from health 
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facilities mentioned above and curried in the CIPDCR/
KEMRI laboratory. These samples were accompanied 
by detailed laboratory requisition forms including the 
details of the infants and their mothers in relation to 
HIV medications.
Processing Of Samples
 For Cobas Assay, analyzing of the samples 
followed four major processes. 6mm × 2 disks from the 
DBS were punched and dropped in each tube as folows: 
1. Approximately 1100µl of Roche specimen specks 
was added to each tube. 
2. Approximately 1000 µl of negative and low 
positive controls were added into separate empty 
tubes and vortexed for 20 seconds. 
3. The mixed samples and reagents were thermo-
mixed at 560C for 10 minutes at 1000rpm, 
incubated and loaded onto the COBAS AmpliPrep 
instrument for sample and control processing. 
 
 During this period, all processed samples and 
controls were not allowed to be exposed to light after 
completion of sample and control preparation. 
 Racks containing processed controls, samples 
and master mix were loaded in the Taqman analyzer 
within 120 minutes after being processed. After the 
samples and controls had been analyzed in the Taqman 
Analyzer, the reports were printed and reported. Flags 
and error messages were checked.  
 For HIV negative control, Cobas TaqMan [CTM 
(-) C] must yield a ‘Target Not Detected’ result for it 
to be valid.  For low positive control, the assigned titre 
range for HIV-1 L(+)is specific for each lot of reagents 
 The HIV-1 low positive controls should fall 
within the provided ranges. If the positive controls are 
flagged as invalid, then the entire batch is invalid and the 
entire process is repeated. For quality control purposes, 
all the samples that tested HIV-positive were re-tested to 
confirm their status by the same individual to maintain 
consistency in sample preparations and analyses. 
Data analysis
 Data analyses were performed using SPSS® 
statistical software package version 19.0 (IBM SPSS 
Inc., Chicago, IL, USA). Simple descriptive statistics 
was used to calculate frequency.  Fleiss’ kappa test 
was used in determining the reliability, accuracy and 
reproducibility of the repeated tests.
Results
A total of 16069 infants from equivalent number of HIV 
infected mothers were recruited for the period of four 
years from four referral hospitals. A total of 3870, 3787, 
4241, 4171 were recruited from Vihiga, Busia, Bungoma 
and Kakamega hospitals respectively (Table 1).
Table 1: Total Number Of Infants Recruited From Each Health Facility
Referral County  
hospitals
Vihiga Busia Bungoma Kakamega Total
2010 901 998 1111 1200 4210
2011 869 984 1150 1090 4093
2012 1200 1106 1300 1080 4686
2013 900 699 680 801 3080
Total 3870 3787 4241 4171 16069
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Figure 2: Trend Of Hiv Infection Among Infants Whose Mothers Were On Various ARVS
Fig 1: Trends of HIV Status Of Infants Recruited  
 Out of the total 4210; 4093; 4686 and 3080 
infants who were recruited in 2010; 2011; 2012 and 
2013 respectively (Table 1), 409(9.7%), 350(8.5%); 
368(7.9%) and 221(7.2%) were HIV positive 
respectively (Figure 1).
 A total of 11,389 (71%) mothers were 
put on ARVs while 4,680 (29%) were not. In 
general, mothers who were put on AZT+3TC+EFV 
(3929) were slightly more compared to those on 
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2010 to 2011 2011 to 2012 2012 to 2013
1.3 2.8 0.3 1.5
AZT+3TC+ NVP
1 1.4 0.8 1.1
SdNVP
2.9 1.2 0.2 1.1
No ARVs uptake
1.4 0.1 0.2 0.6
 Table 2: shows differences of HIV prevalence 
of infants whose mothers were taking specific ARVs 
within subsequent years.
1. On average, infants whose mothers were put 
on AZT+3TC+EFV had 1.5% HIV prevalence 
reduction 
2. while infants whose mothers were put on 
AZT+3TC+NVP and SdNVP had a reducing 
transmission prevalence of 1.1% each. 
3. Those infants whose mothers were not taking any 
ARVs had an increasingly transmission of HIV 
prevalence of 0.6%
1. Trends of HIV in infants whose mothers were  
 put on AZT+3TC+EFV was:
  
  2010  -  10.4%, 
  2011  -  9.1%, 
  2012  -  6.3% and
  2013  -  6.0%  respectively.  
2. Trends of HIV in infants whose mothers were   
 put on AZT+3TC+NVP was: 
  
  2010  -  7.1%, 
  2011  -  6.1%, 
  2012  -  4.7% and
  2013  -  3.9% respectively.
3. Trends of HIV in infants whose mothers were  
 put on SdNVP was: 
  
  2010  -  10.3%
  2011  -  7.4%
  2012  -  6.2%
   2013  -  6.0% respectively. 
4. However, for the mothers who were not taking  
 any ARVs the trend was:
  
  2010  -  11.2%
  2011  -  12.6% 
  2012  -  12.7%  
  2013  -  12.9% respectively.
African Journal of Health Sciences  Volume 32, Number 3, May - June 201934
Discussion
 Pregnant women with HIV infection should 
receive standard clinical, immunologic, and virologic 
evaluation. They should be offered appropriate 
Antiretroviral therapy for their own health and for 
prevention of perinatal transmission of HIV, consistent 
with the principles of treatment for non-pregnant adults. 
 Therefore, the objective of this study was to 
determine the trend of HIV infection among infants 
born to HIV infected mothers. This is in relation to 
specific ARVs administration among pregnant women 
and mothers of 18 and below months old infants. 
 The samples were collected from infants 
attending all the four referral health facilities in Western 
part of Kenya providing Prevention-of-Mother-to-Child 
Transmission (PMTCT) and HIV management services. 
Services such as HIV testing, CD4 counts, ARVs and 
anti-TB drugs for both mothers and their infants. 
 Most participants were recruited in 2012 
compared to other years. This is perhaps the game 
changer in 2011 with unprecedented progress in science, 
political leadership and results for the AIDS response 
[35, 36].
 
 The recent study shows a decrease in the trends 
of HIV infections among infants whose mothers were 
put on various ARVs from 2010 to 2013. Similar pattern 
to the decreasingly HIV trend of the  National [32, 37, 
38]. 
 The continuous decrease in HIV infections 
could be due to various HIV interventions that are 
being practiced in the health sector [36, 39, 40] and 
a commitment the leaders have to redouble efforts to 
achieve a universal access to HIV prevention, treatment, 
care and support as critical steps towards ending the 
global HIV epidemic by 2015. Targeting to achieving 
the Millennium Development Goal 6, in particular to 
halt and begin to reverse the spread of HIV [35]
 The study shows that, a higher percentage (71%) 
of mothers were put on various ARVs and only 29% 
were not. This could be due to the degree that, all HIV 
infected breastfeeding mothers and pregnant women 
should access PMTCT and be put on ARVS to reduce 
the scourge [41, 42].
 The ART coverage in the current study was 
more than the global 62% ART coverage probably due 
to the PMTCT interventions [36, 39, 40]. unlike lower 
than the coverage of 90% for four prioritized countries, 
namely  Botswana, Ghana, Namibia and Zambia [43]. 
 In general the number of mothers who were 
taking the three types of ARVs were comparable and 
almost similar due to the fact that all the three regimens 
are available and listed in the national guidelines of 
most low and middle income countries. They are also 
recommended for use in pregnant women who need 
ART [44].
 In the current study, the trend of HIV is seen 
to decrease with subsequent years among infants whose 
mothers were put on ARVS and increase among infants 
whose HIV positive mothers were not taking ARVs. 
This supports the idea that ARVs uptake reduces HIV 
transmission from mothers to their children [45-47]
 The reduction of the rate of transmission 
within subsequent years was seen to be higher among 
infants whose mothers were put on combined ART 
therapy (AZT+3TC+ EFV) than combined ART therapy 
(AZT+3TC+ NVP) and Single dose Nevirapine. Possible 
explanations for these findings include the greater 
antiviral activity of EFV versus NVP [48].
 Although   AZT+3TC+NVP is relatively safe, 
well tolerated and gives excellent virological suppression 
in mothers [44]. Some studies have found EFV to result 
into slightly less side effects and more likely to prevent 
death than NVP. 
 To add on that, AZT+3TC+ EFV is associated 
with less risk of resistance when comparing with 
AZT+3TC+ NVP and SdNVP [49]
Limitation of the study
 Part of our limitation was that we did not 
investigate why some mothers were not put on ARVs. 
Some confounding factors like breastfeeding, caesarean 
type of delivery which might have affected the trend 
of HIV transmission from mothers to infants were not 
investigated. 
Conclusions
 There is a direct relationship between specific 
ARV administration and HIV infection among these 
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infants. This is evident by the fact that HIV appeared to 
decrease with sub-sequent years of provision of specific 
drugs. HAART (AZT+3TC+EFV) seemed to provide 
greater impact in HIV prevention compared to other 
two ARVs. There is need for all pregnant women to be 
put on ARVs to reduce the transmission of HIV from 
mothers to their infants.
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